NECTIN4 could promote the lymphangiogenesis via CXCR4/CXCL12 axis, and antibody-drug conjugates (ADC) targeting NECTIN4 have been utilized for the treatment of solid tumors.26GABRP enhanced infiltration of macrophage through CXCL5/CCL20, facilitating tumor progression.27 Oncogenes highly expressed before therapy tended to remodel TME and sensitize tumor cells to immunotherapy. The gene discussed is CXCR4; the disease is neoplasm.